Tessera Therapeutics Showcases New Preclinical Data Advancing In Vivo Program in Sickle Cell Disease and CAR-T Applications at the American Society of Gene and Cell Therapy 29th Annual Meeting
Presented improved editing data in non-human primates (NHP) for sickle cell disease (SCD), demonstrating a single dose of Gene Writer achieved an average of 85% of long-term hematopoietic stem cells